Andrew Jess Dannenberg

From Wikipedia, the free encyclopedia

Andrew Jess Dannenberg (born 17 February 1956) is a U.S. physician and researcher, currently Henry R. Erle, M.D. - Roberts Family Professor of Medicine at Weill Medical College/M.D. Anderson Cancer Center. He additionally holds the positions there of Professor of Medicine in Cardiothoracic Surgery and Director of Cancer Prevention. He received a B.s. from Tufts University in 1978 and a M.D. from Washington University School of Medicine in 1982.

Contents

[edit] NSAIDs and cancer controversy

In January 2006, it was revealed that an article (The Lancet, October 2005) he had co-authored with Norwegian researcher Jon Sudbø was a scientific misconduct and retracted. [1] The paper had reported on the side effects of other NSAIDs on oral cancer, saying "Our findings highlight how a commonly used drug can have a benefit from the standpoint of cancer prevention but can also have side effects - in this case, an increased risk for cardiovascular death ..." [2] [3] [4]

According to the Norwegian daily Verdens Gang, Dannenberg may have been instrumental in the conception of the article ([1], in Norwegian). An independent Commission of Inquiry led by Swedish Professor Anders Ekbom found no evidence that any of his co-authors had taken part in the fraud or otherwise been party to the deceit.[5]

[edit] Honors

  • Upjohn Achievement Award for scientific research
  • American Liver Foundation Scholar Award and the
  • International Life Sciences Research Foundation Award.

[edit] Publications

His current work deals with the role of cyclooxygenase-2 (COX-2) in cancer. [6] ,[7], [8] He has previously been one of the three lead investigators of a major study on the role of aspirin in the prevention of breast cancer. [9].

[edit] Journals

According to Web of Science, he has published over 200 peer-reviewed articles, of which 27 have cited over 100 times. The most cited are:

  • "Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis" by Boolbol SK, Dannenberg AJ, Chadburn A, in Cancer Research 56(11)2556-2560 (1996) Times Cited: 401
  • "Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer" by Tucker ON, Dannenberg AJ, Yang FK, et al. in Cancer Research 59 (5) 987-990 (1999)Times Cited: 386
  • "Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck" by Chan G, Boyle JO, Yang EK, et al. in Cancer Research 59 (5) 991-994 (1999) Times Cited: 384
  • "COX‐2 is expressed in human pulmonary, colonic, and mammary tumors" RA Soslow, AJ Dannenberg, D Rush, BM Woerner, KN. in Cancer: 89 ( 12) 2637-2645 (2000) Times Cited: 289

[edit] Editor

  • COX-2: A New Target for Cancer Prevention and Treatment ed. by R. N. Dubois and A. J. Dannenberg Basel ; New York : Karger, 2003. ISBN: 380557536X 978380557536
  • The role of COX-2 carcinogenesis by Andrew J Dannenberg; Raymond N Dubois; Steven M Dubinett; Nasser K Altorki; et al Philadelphia, PA : Saunders, 2004. OCLC: 66570293
  • Peptic ulcer disease and other acid-related disorders by David Zakim; Andrew J Dannenberg Armonk, N.Y. : Academic Research Associates, 1991. ISBN: 9780962918001

[edit] References

  1. ^ Horton, Richard. "Retraction — Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study", The Lancet, 4 February 2006. Retrieved on 2008-03-26. 
  2. ^ "Use Of Non-COX-2-specific NSAIDs Halves Odds For Oral Cancer: Doubles Cardiovascular Death Risk", Science Daily, October 7, 2005. Retrieved on 2008-03-26. "An analysis of 20 years of data on the health of over 900 adults has found that long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, cuts the risk for oral cancer in smokers by half." 
  3. ^ Dannenberg, Andrew. "Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study", The Lancet, October 15, 2005. Retrieved on 2008-03-26. "Non-steroidal anti-inflammatory drugs (NSAIDs) seem to prevent several types of cancer, but could increase the risk of cardiovascular complications. We investigated whether use of NSAIDs was associated with a change in the incidence of oral cancer or overall or cardiovascular mortality." 
  4. ^ "Fraud charges against Norwegian researcher stoke confusion over painkillers", Associated Press, January 17, 2006. Retrieved on 2008-03-26. "Fraud accusations against a Norwegian researcher have muddied the question of whether popular over-the-counter pain relievers fight cancer or harm the heart. Norway's Comprehensive Cancer Center said over the weekend that one of its researchers admitted fabricating data used in a study that said common pain relievers, including ibuprofen (sold as Motrin and Advil) and naproxen (Naprosyn, Aleve), lowered the risk of oral cancer but heightened the risk of heart problems...." 
  5. ^ Kihlström, Staffan. "60 forskare granskas efter fuskskandal", Dagens Nyheter, 2006-05-06. (Swedish) 
  6. ^ " COX-2 Inhibitors for Cancer Prevention & Treatment: Research Roundup: " by Lindsey, Heather Oncology Times
  7. ^ " COX-2 Inhibitors: Cancer Trials Test New Uses for Pain Drug" by Jennifer Michalowski Journal of the National Cancer Institute 24(4)April 2002p 52-54
  8. ^ "Researchers Plan To Continue To Study COX-2 Inhibitors in Cancer Treatment and Prevention" by Cori Vanchieri. JNCI Spectrum (with portrait)
  9. ^ "Women who regularly take aspirin at lower risk of breast cancer" Women's Health News Monday, 31-May-2004

[edit] External links

 This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it.